Agilent Technologies Inc. has received the 2006 Frost & Sullivan Growth Strategy Leadership Award for using research, collaboration and innovation to become a global leader in providing core bio-analytical and electronic measurement solutions to accelerate the design, discovery and development of new products to various markets, including the life sciences industry.
"Backed by an established technology platform, Agilent offers customers a comprehensive range of application-focused solutions," says Frost & Sullivan Programme Leader - Drug Discovery Technologies, Dr. Amarpreet Dhiman. "The company's two segments help significantly advance critical customer needs - electronic measurement segment providing standard and customised electronic measurement instruments and systems and the bio-analytical measurement segment providing application-focused solutions that include instruments, software, consumables, and services that enable customers to identify, quantify, and analyse the physical and biological properties of substances and products."
Agilent's flagship product- the 2100 Bioanalyzer- used for the analysis of DNA, RNA, proteins and cells, is designed to streamline RNA isolation, gene expression analysis, gene silencing, protein purification analysis, protein quality control as well as integrated cell-based parameter acquisition from as few as 20,000 cells per sample.
Equally exceptional is the HPLC-Chip/MS system, used for nanoflow electrospray LC/MS that integrates enrichment column, hydraulic connections and electrospray emitter on a single polymer chip.
"With net revenues totalling over $5.1 billion in 2005 and a presence in over 110 countries, Agilent Technologies continues to successfully complement its technological edge over the industry by encompassing a range of disciplines, with the aim of capitalising on a larger marketplace," observes Dr. Dhiman. "A cutting-edge product range, strong investment flows, judicious industrial collaborations, an exceptional IP portfolio and an innovative commercialisation strategy have given the firm the potential to expand its base of large customers, and strike more licensing deals."
Click here for more information
